Improved Core Operating Income
Core operating income increased by JPY22 billion YoY to JPY27.7 billion, indicating improved recurring earnings power.
Sumitomo Pharma Performance
Core operating income for Sumitomo Pharma was JPY21 billion, an increase of JPY20.1 billion YoY, driven by operational streamlining and increased shipments of key products.
Essential and Green Materials Segment Improvement
Core operating income loss reduced by JPY14.1 billion YoY, due to improved profit margins in synthetic resins and refining margins at Petro Rabigh.
Positive Cash Flows from Operating Activities
Cash flows from operating activities resulted in a positive inflow of JPY24 billion, up by JPY36.3 billion YoY.